MedPath

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 3
Completed
Conditions
Plaque Psoriasis
Interventions
Biological: ABT-874
Biological: etanercept
Drug: placebo
Registration Number
NCT00691964
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Brief Summary

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
347
Inclusion Criteria
  • Diagnosis of Psoriasis for 6 mo.
  • BSA 10%, PASI 12 or above, PGA 3 or above
Exclusion Criteria
  • Previous exposure to either etanercept or ABT-874

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AABT-874-
Betanercept-
Cplacebo-
Primary Outcome Measures
NameTimeMethod
Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 1212 Weeks
Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 1212 Weeks
Secondary Outcome Measures
NameTimeMethod
Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 1212 Weeks

Trial Locations

Locations (35)

Site Reference ID/Investigator# 8471

🇺🇸

Philadelphia, Pennsylvania, United States

Site Reference ID/Investigator# 9641

🇺🇸

Miami, Florida, United States

Site Reference ID/Investigator# 8464

🇺🇸

Boston, Massachusetts, United States

Site Reference ID/Investigator# 8468

🇺🇸

Cincinnati, Ohio, United States

Site Reference ID/Investigator# 8460

🇺🇸

Cleveland, Ohio, United States

Site Reference ID/Investigator# 8479

🇺🇸

Arlington Heights, Illinois, United States

Site Reference ID/Investigator# 8467

🇺🇸

Indianapolis, Indiana, United States

Site Reference ID/Investigator# 8478

🇺🇸

Tucson, Arizona, United States

Site Reference ID/Investigator# 8462

🇺🇸

Fresno, California, United States

Site Reference ID/Investigator# 8447

🇺🇸

Albuquerque, New Mexico, United States

Site Reference ID/Investigator# 9762

🇺🇸

Oklahoma City, Oklahoma, United States

Site Reference ID/Investigator# 8469

🇺🇸

Portland, Oregon, United States

Site Reference ID/Investigator# 8454

🇺🇸

Los Angeles, California, United States

Site Reference ID/Investigator# 8459

🇺🇸

St. Louis, Missouri, United States

Site Reference ID/Investigator# 9001

🇺🇸

Skokie, Illinois, United States

Site Reference ID/Investigator# 8473

🇺🇸

East Windsor, New Jersey, United States

Site Reference ID/Investigator# 8457

🇺🇸

New Brunswick, New Jersey, United States

Site Reference ID/Investigator# 8475

🇺🇸

New York, New York, United States

Site Reference ID/Investigator# 8456

🇺🇸

Greer, South Carolina, United States

Site Reference ID/Investigator# 8458

🇺🇸

Goodlettsville, Tennessee, United States

Site Reference ID/Investigator# 8461

🇺🇸

Austin, Texas, United States

Site Reference ID/Investigator# 10542

🇺🇸

Dallas, Texas, United States

Site Reference ID/Investigator# 8452

🇺🇸

Houston, Texas, United States

Site Reference ID/Investigator# 8474

🇺🇸

San Antonio, Texas, United States

Site Reference ID/Investigator# 9566

🇺🇸

Portland, Oregon, United States

Site Reference ID/Investigator# 8449

🇺🇸

Johnston, Rhode Island, United States

Site Reference ID/Investigator# 8448

🇺🇸

Providence, Rhode Island, United States

Site Reference ID/Investigator# 8463

🇺🇸

Alpharetta, Georgia, United States

Site Reference ID/Investigator# 8527

🇺🇸

Schaumburg, Illinois, United States

Site Reference ID/Investigator# 8466

🇺🇸

West Dundee, Illinois, United States

Site Reference ID/Investigator# 8476

🇺🇸

Denver, Colorado, United States

Site Reference ID/Investigator# 8480

🇺🇸

Lake Oswego, Oregon, United States

Site Reference ID/Investigator# 8482

🇺🇸

Tyler, Texas, United States

Site Reference ID/Investigator# 9761

🇺🇸

Hershey, Pennsylvania, United States

Site Reference ID/Investigator# 8472

🇺🇸

Norfolk, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath